Developed by Genoscience professor Philippe Halfon , BL-8020 acts by inhibiting Hepatitis C virus (HCV)-induced autophagy, which differs from the mechanism of currently used anti-HCV agents.
The pre-clinical studies have demonstrated that BL-8020, when integrated with other anti-Hepatitis C virus (HCV) agents, has a synergistic effect.
The company said use of two drugs which are acting by different mechanisms is also likely to benefit patients who have developed resistance to current treatments.
BioLineRx CEO Kinneret Savitsky said BL-8020 has demonstrated safety and efficacy profile, and is found to shorten therapy duration and combat resistance by acting as an add-on platform.